The CYCC chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYCC chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CYCC stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CYCC Detailed Price Forecast - CNN Money||View CYCC Detailed Summary - Google Finance|
|View CYCC Detailed Summary - Yahoo! Finance||View CYCC Stock Research & Analysis - Zacks.com|
|View CYCC Trends & Analysis - Trade-Ideas||View CYCC Major Holders - Barrons|
|View CYCC Call Transcripts - NASDAQ||View CYCC Breaking News & Analysis - Seeking Alpha|
|View CYCC Annual Report - CompanySpotlight.com||View CYCC OTC Short Report - OTCShortReport.com|
|View CYCC Fundamentals - TradeKing||View CYCC SEC Filings - Bar Chart|
|View Historical Prices for CYCC - The WSJ||View Performance/Total Return for CYCC - Morningstar|
|View the Analyst Estimates for CYCC - MarketWatch||View the Earnings History for CYCC - CNBC|
|View the CYCC Earnings - StockMarketWatch||View CYCC Buy or Sell Recommendations - MacroAxis|
|View the CYCC Bullish Patterns - American Bulls||View CYCC Short Pain Metrics - ShortPainBot.com|
|View CYCC Stock Mentions - StockTwits||View CYCC Stock Mentions - PennyStockTweets|
|View CYCC Stock Mentions - Twitter||View CYCC Investment Forum News - Investor Hub|
|View CYCC Stock Mentions - Yahoo! Message Board||View CYCC Stock Mentions - Seeking Alpha|
|View Insider Transactions for CYCC - SECform4.com||View Insider Transactions for CYCC - Insider Cow|
|View CYCC Major Holdings Summary - CNBC||View Insider Disclosure for CYCC - OTC Markets|
|View Insider Transactions for CYCC - Yahoo! Finance||View Institutional Holdings for CYCC - NASDAQ|
|View CYCC Stock Insight & Charts - FinViz.com||View CYCC Investment Charts - StockCharts.com|
|View CYCC Stock Overview & Charts - BarChart||View CYCC User Generated Charts - Trading View|
What does Cyclacel Pharmaceuticals Inc’s (NASDAQ:CYCC) Balance Sheet Tell Us About Its Future?
Posted on Thursday September 20, 2018
The direct benefit for Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...
Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors
Posted on Wednesday September 12, 2018
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced the appointment of Robert Spiegel, M.D., FACP, to its Board of Directors. "We are very pleased to have Dr. Robert Spiegel join the Board of Directors of Cyclacel.
Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer
Posted on Monday September 10, 2018
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announced the initiation of a Phase 1b/2 investigator-sponsored clinical trial to evaluate the safety and effectiveness of sapacitabine in combination with olaparib in patients with BRCA mutant breast cancer. The trial will be conducted at the Dana-Farber Cancer Institute with collaborators Cyclacel and AstraZeneca providing sapacitabine investigational drug and the approved PARP-inhibitor olaparib (LynparzaTM), respectively.
Factors of Influence in 2018, Key Indicators and Opportunity within Aerie Pharmaceuticals, BioScrip, Celsion, Primoris Services, Cyclacel Pharmaceuticals, and Barnes Group — New Research Emphasizes Economic Growth
Posted on Wednesday September 05, 2018
NEW YORK, Sept. 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...